HSPA5 and obesity disorder: Indeed, HSPA5 inhibitors interfere with SARS-CoV-2 infection (Palmeira et al. 2020), corroborating this hypothesis, while HSPA5 levels might predispose to a severe progression and outcome of COVID-19 in patients with older age, obesity, and diabetes (Shin et al. 2021).